Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids

Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids

Contact

 If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is now recruiting. Learn more about enrolling here.

Description
This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory"). Part B enrolls patients with a relapsed or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor, Wilms tumor, or tumors with changes in a gene family known as the Wnt pathway. This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose. 

What to expect
Participants in the research will:
  • Receive a study drug called tegavivint
  • Complete frequent clinic visits at CHOP
  • Have frequent blood tests
  • Have DEXA scans to measure your bone density
  • Have knee x-rays if under the age of 18
  • Have extra or leftover tissue collected if they have a biopsy as part of regular cancer care
  • Have periodic electrocardiograms (ECGs)

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.